AMENDMENT TO SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 27th, 2017 • Tianjin Pharmaceuticals Group Holdings Co., Ltd. • Biological products, (no disgnostic substances) • New York
THIS AMENDMENT TO SECURITIES PURCHASE AGREEMENT (the “Amendment”) is entered into as of December 1, 2016 by and among Neuralstem, Inc., a Delaware corporation (the “Company”), Tianjin Pharmaceutical Holdings, Ltd. (the “Assignor” or “Initial Purchaser”), and Tianjin Pharmaceuticals Group International Holdings Co., LTD., a British Virgin Islands entity (the “Assignee” or the “Purchaser”), for the purpose of amending the Securities Purchase Agreement dated September 7, 2016 (the “Agreement”). Capitalized terms not defined in this Amendment but used herein have the meanings given such terms in the Agreement.
JOINT FILING AGREEMENTJoint Filing Agreement • February 27th, 2017 • Tianjin Pharmaceuticals Group Holdings Co., Ltd. • Biological products, (no disgnostic substances)
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D and any amendment thereto need be filed with respect to the ownership by each of the undersigned of shares of stock of Neuralstem, Inc.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 27th, 2017 • Tianjin Pharmaceuticals Group Holdings Co., Ltd. • Biological products, (no disgnostic substances) • Delaware
This Registration Rights Agreement (the “Agreement ”) is made as of December 1, 2016 by and among Neuralstem, Inc., a Delaware corporation (the “Company ”) and Tianjin Pharmaceuticals Group International Holdings Co., Ltd (the “ Investor ”).
